MedTrace Logo

Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis

NCT00132041 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2020-09-10

Study results available
· View outcomes & findings →

Summary

RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. CT-, MRI-, or ultrasound-guided radiofrequency ablation may be an effective treatment for liver cancer and cirrhosis.

PURPOSE: This phase II trial is studying how well radiofrequency ablation works in treating patients with liver cancer and cirrhosis.

Conditions

Interventions

DEVICE

radiofrequency ablation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • American College of Radiology Imaging Network

    lead NETWORK

Principal Investigators

  • Gerald D. Dodd, MD · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2009-08-31
Completion
2010-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132041 on ClinicalTrials.gov